Mastocytosis is a clonal disorder driven by KIT mutations, but resistance to tyrosine kinase inhibitors (TKIs) remains a major challenge. Following the discovery of an AXL L197M mutation in a patient with congenital aggressive mastocytosis, we demonstrated unexpected wild-type AXL expression in neoplastic mast cells (MCs) across mastocytosis subtypes, challenging current views concerning mastocytosis pathophysiology. AXL was undetectable in steady-state…
AXL mediates mast cell survival and resistance to tyrosine kinase inhibitors in mastocytosis
bioRxiv Cancer Biology | | Kangboonruang, K., Drabent, P., Heintze, M., Maksut, F., Lepelletier, Y., Lhermitte, L., Feroul, M., Letard, S., Kabore, C., Brenet, F., Meni, C., Cagnard, N., Bondet, V., Lefevre, G., Bruneau, J., Dussiot, M., Halse, H., Bigorgne, A., Collange, A.-F., Bouktit, H., Retornaz, F., Megret, J., Barete, S., Droin, N., Bulai Livideanu, C., Lebouvier, A., Duffy, D., Solary, E., Arock, M., Gandhi, D., Bodemer, C., Rossignol, J., Polivka, L., Molina, T., Hermine, O., Maouche-Chretien, L.
Topics: blood-cancer, targeted-therapy, research